Back

School immunization coverage during the COVID-19 pandemic: A retrospective cohort study

Sell, H.; Paudel, Y. R.; Voaklander, D.; MacDonald, S. E.

2022-05-07 epidemiology
10.1101/2022.05.04.22274665 medRxiv
Show abstract

Few studies have assessed the impact of the COVID-19 pandemic on immunization coverage for adolescents, and little is known about how coverage has changed throughout the pandemic. We aimed to: (1) assess the change in coverage for school-based vaccines in Alberta, Canada resulting from the pandemic; (2) determine whether coverage differed by geographic health zone and school type; and (3) ascertain whether coverage has returned to pre-pandemic levels. Using a retrospective cohort design, we used administrative health data to compare coverage for human papillomavirus (HPV) and meningococcal conjugate A, C, Y, W-135 (MenC-ACYW) vaccines in Alberta, Canada between pre-pandemic (2017-2018 school year) and pandemic (2019-2020 and 2020-2021 school years) cohorts (N=289,420). Coverage was also compared by health zone and authority type. The 2019-2020 cohort was followed over one year to assess catch-up. Compared to 2017-2018, immunization coverage for HPV was significantly lower in the 2019-2020 (absolute difference: 60.8%; 95% CI: 60.4-61.3%) and 2020-2021 cohorts (absolute difference: 59.9%; 95% CI: 59.4-60.3%). There was a smaller, significant decline in MenC-ACYW coverage comparing 2017-2018 to 2019-2020 (absolute difference: 6.1%; 95% CI: 5.6-6.5%) and 2020-2021 (absolute difference: 32.2%; 95% CI: 31.6-32.7%). Private schools had low coverage overall, while coverage fluctuated by zone. During follow-up of the 2019-2020 cohort, coverage for HPV and MenC-ACYW increased from 5.6% to 50.2%, and 80.7% to 83.0%, respectively. There was a substantial decrease in school-based immunization coverage during the COVID-19 pandemic, and coverage has not returned to pre-pandemic levels, suggesting further catch-up is needed.

Matching journals

The top 1 journal accounts for 50% of the predicted probability mass.

1
Vaccine
189 papers in training set
Top 0.1%
55.1%
50% of probability mass above
2
PLOS ONE
4510 papers in training set
Top 33%
4.6%
3
The Lancet Regional Health - Americas
22 papers in training set
Top 0.1%
3.8%
4
Vaccine: X
19 papers in training set
Top 0.1%
3.2%
5
BMC Public Health
147 papers in training set
Top 3%
2.0%
6
Clinical Infectious Diseases
231 papers in training set
Top 2%
2.0%
7
Eurosurveillance
80 papers in training set
Top 0.6%
1.9%
8
Vaccines
196 papers in training set
Top 1%
1.4%
9
American Journal of Epidemiology
57 papers in training set
Top 0.9%
1.4%
10
International Journal of Epidemiology
74 papers in training set
Top 2%
1.3%
11
PLOS Medicine
98 papers in training set
Top 3%
1.0%
12
Open Forum Infectious Diseases
134 papers in training set
Top 2%
0.9%
13
BMJ Open
554 papers in training set
Top 11%
0.9%
14
CMAJ Open
12 papers in training set
Top 0.2%
0.8%
15
International Journal of Cancer
42 papers in training set
Top 1%
0.8%
16
Human Vaccines & Immunotherapeutics
25 papers in training set
Top 0.7%
0.8%
17
Frontiers in Public Health
140 papers in training set
Top 8%
0.8%
18
Scientific Reports
3102 papers in training set
Top 77%
0.7%
19
International Journal of Environmental Research and Public Health
124 papers in training set
Top 7%
0.7%
20
Travel Medicine and Infectious Disease
15 papers in training set
Top 0.9%
0.5%
21
PLOS Neglected Tropical Diseases
378 papers in training set
Top 6%
0.5%
22
Journal of Travel Medicine
18 papers in training set
Top 0.4%
0.5%
23
Emerging Infectious Diseases
103 papers in training set
Top 4%
0.5%
24
Epidemiology and Infection
84 papers in training set
Top 4%
0.5%